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Abstract
Background: After the implementation of 7-valent pneumococcal conjugate vaccine (PCV7), in several countries,
serotype 19A is now the serotype most frequently involved in pneumococcal diseases and carriage. To determine
factors potentially related to 19A nasopharyngeal (NP) carriage we analyzed data from an ongoing prospective
French national surveillance study of pneumococcal NP carriage in young children.
Methods: NP swabs were obtained from children aged 6 to 24 months, either during routine check-ups with
normal findings, or when they presented with acute otitis media (AOM). The swabs were sent for analysis to the
French National Reference Centre for Pneumococci. Factors influencing pneumococcal carriage and carriage of
penicillin non-susceptible (PNSP), 19A and PNS-19A were investigated by multivariate logistic regression.
Results: From 2006 to 2009, 66 practitioners enrolled 3507 children (mean age 13.6 months), of whom, 98.3% of
children had been vaccinated with PCV7 and 33.4% of children attended daycare centres (DCC). Serotype 19A was
found in 10.4% of the overall population, 20.5% of S. pneumoniae carriers (n = 1780) and 40.8% of PNSP carriers (n
= 799). Among 19A strains, 10.7% were penicillin-susceptible, 80% intermediate and 9.3% fully resistant. Logistic
regression analysis showed that the main factors associated with PNSP carriage were AOM (OR = 3.09, 95% CI
[2.39;3.98]), DCC (OR = 1.70, 95% CI [1.42;2.03]), and recent antibiotic use (OR = 1.24, 95% CI [1.05;1.47]. The main
factors predictive of 19A carriage were recent antibiotic use (OR = 1.81, 95% CI [1.42;2.30]), AOM (OR = 1.67, 95% CI
[1.11;2.49]), DCC (OR = 1.56, 95% CI [1.21;2.2] and young age, <12 months (OR = 1.51, 95% CI [1.16;1.97]).
Conclusion: In a population of children aged from 6 to 24 months with a high rate of PCV7 vaccination coverage,
we found that antibiotic exposure, DCC attendance and AOM were linked to 19A carriage.
Background
An increase in the incidence of S. pneumoniae serotype
19A isolation has been observed in many countries, and
19A is now the serotype most frequently isolated from
patients with invasive and mucosal pneumococcal dis-
eases [1-4]. Serotype 19A is also a frequent nasopharyn-
geal (NP) carriage serotype, and is frequently resistant
to antibiotics [3,5,6]. Most non-PCV7 serotypes do not
share all of these properties, and it is important to iden-
tify factors determining carriage serotype patterns [7]. In
France, the increasing involvement of serotype 19A in
NP carriage, AOM and invasive disease is related to clo-
nal expansion of the pre-existing penicillin-intermediate
ST 276, [5,8] whereas in the US the increase in serotype
19A is mainly attributed to ST199 and the multidrug-
resistant clone ST 320 [4]. Vaccine escape was first
reported in the US by Brueggeman et al. Around 2003,
recombination occurred between the recipient ST695
serotype 4 and donor ST199 serotype 19A, simulta-
neously resulting in the non vaccine capsular type and
penicillin intermediate-resistant ST695 19A pneumo-
cocci. With the additional selective advantage of penicil-
lin non susceptibility, the ST695 19A variant continued
to spread, becoming in 2007 the fourth most common
serotype 19A clonal complex in the US [9]. In several
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implementation of 7-valent pneumococcal conjugate
vaccine (PCV7) [4,10] but in Israel and South Korea an
increase was noted before the vaccine era, and the
observed association with antibiotic use pointed to a
role of secular variations [11,12]. The NP flora is the
main ecological niche of S. pneumoniae (Sp), and the
onset of invasive and non invasive diseases is often pre-
ceded by carriage acquisition [13,14]. The marked
decline in vaccine serotypes observed since PCV7 was
implemented has made room for non vaccine serotypes
(NVS) including 19A. We therefore examined factors
potentially related to 19A NP carriage by analyzing data
from an ongoing prospective French national surveil-
lance study of pneumococcal NP carriage in young chil-
dren [8,15].
Methods
From November 2006 to June 2009, 66 French pediatri-
cians and general practitioners distributed throughout
France took part in a cross-sectional study. An NP swab
was obtained from children aged 6 to 24 months, either
during routine check-ups with normal findings, or when
they presented with AOM. Children were excluded from
the study if they had received antibiotics within 7 days
before enrolment, or had a severe underlying health dis-
order, or had already been included in the study during
the previous 12 months. Demographic data, the medical
history and physical findings were recorded. The study
was approved by the Saint Germain en Laye Ethics
Committee, and written informed consent was obtained
from the parents or guardians. Nasopharyngeal speci-
mens were obtained with cotton-tipped wire swabs. The
swabs were inserted into the anterior nares, gently
rubbed on the nasopharyngeal wall and immediately
placed in transport medium (Copan Venturi Transys-
tem
®,B r e s c i a ,I t a l y ) .T h es a m ples were transferred
within 48 hours to the French National Reference Cen-
tre for Pneumococci. S. pneumoniae culture, identifica-
tion, serotyping and antibiotic susceptibility testing were
performed as previously described [15]. Susceptibility of
S. pneumoniae isolates to penicillin G was determined
from minimal inhibitory concentrations (MICs) by the
agar-dilution method. Isolates were classified as penicil-
lin-susceptible (MIC ≤ 0.06 μg/ml), intermediate (0.12 ≤
MIC ≤ 1.0 μg/ml) or fully resistant (MIC ≥ 2 μg/ml) as
recommended by the Antibiogram Committee of the
French Society of Microbiology [8,15,16].
Data were double-entered using 4D software (version
6.4), and analysed using Stata SE 9.1 (Stata Corp., Col-
lege Station, TX, USA) for univariate analysis and multi-
variate logistic regression (odds ratios [ORs] and 95%
confidence intervals [CI]). The Pearson Chi-square test
was used in univariate analysis to identify factors related
(P < 0.10) to NP carriage of pneumococci, serotype 19A,
and penicillin non-susceptible pneumococci (PNSP =
intermediate + resistant: MIC ≥ 0.12 μg/ml) [16]. 19A
serotype and penicillin non susceptible 19A serotype
(PNS-19A) carriage was also separately analysed among
Sp and PNSP carriers, respectively. Variables identified
by univariate analysis were age, gender, the study group
(healthy controls vs children with AOM), PCV7 vaccina-
tion status, the season, year of enrolment, existence of
siblings, daycare attendance, recent antibiotic treatment
(within 3 months before enrolment), and nasopharyn-
geal carriage of H. influenzae, M. catarrhalis and S. aur-
eus. Winter months were November to March and
spring months April to June. PCV7 vaccination was con-
sidered partial when the primary series of immunization
as recommended in France was incomplete in children
< 12 months or when no booster dose had been admi-
nistered to children ≥12 months, and complete if all
initial injections had been received by age 12 months,
and if the booster dose had been administered to chil-
dren ≥12 months old.
Results
Sixty-six practitioners enrolled 3507 patients (909
healthy controls and 2598 children with AOM). Table 1
shows demographic characteristics and nasopharyngeal
carriage of the children enrolled. Mean age was 13.6 ±
5.2 months (median 12.8) and 98.3% of children had
been vaccinated with PCV7 (partial 21.9%, complete
78.1%). One-third (33.4%) of children attended daycare
centres (DCC), of whom 45.3% had siblings, while 34.5%
of children were kept at home, of whom 68.9% had sib-
lings. The pneumococcal carriage rate was 50.8% in the
overall population. The isolates were penicillin-suscepti-
ble in 54.9% of cases, intermediate in 41.3% and fully
resistant in 3.8%. Figure 1 shows the serotype distribu-
tion and the resistance profile among pneumococcal
carriers according to the serotype. Serotype 19A was
clearly the leading serotype (20.5% of isolates). All PCV7
vaccine types represented less than 11%, serotypes 15A,
15B and 15C respectively 6.1%, 4.3% and 2.6%, and sero-
type 35B, 5.5%. Among 19A strains, 10.7% were penicil-
lin-susceptible, 80% intermediate and 9.3% fully
resistant. Serotype 19A represented 40.8% of PNSP
(326/799). The other non vaccine PNSP serotypes were
35B (10.7%) and 15A (12.2%). Table 2 lists factors influ-
encing pneumococcal carriage and carriage of PNSP,
19A and PNS-19A in logistic regression analysis. Logis-
tic regression analysis showed that the main factors
associated with PNSP carriage were AOM (OR = 3.09,
95% CI [2.39;3.98]), DCC (OR = 1.70, 95% CI
[1.42;2.03]), and recent antibiotic use (OR = 1.24, 95%
CI [1.05;1.47]. Whatever the analysis, logistic regression
c o n f i r m e dt h a tA O M ,D C C ,r e c e n ta n t i b i o t i cu s ea n d
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Sibling status increased the risk of Sp carriage but
reduced the risk of 19A carriage.
Discussion
In multiple surveillance studies, serotype 19A strains
have been identified as major replacement strains in
pneumococcal disease (invasive disease and AOM)
reflecting both their greater predominance in carriage
and their disease potential. However, the importance of
19A as a replacement serotype in invasive diseases,
AOM and NP carriage varies across countries where
PCV7 has been implemented, for reasons that are not
fully understood [5,17,18]. Previous studies have identi-
fied two important factors affecting serotype 19A car-
riage, namely the prevalence prior to PCV7
implementation, and the level of antibiotic use (a large
proportion of 19A strains were non susceptible prior to
Table 1 Demographic characteristics and nasopharyngeal carriage in children with AOM and healthy controls
Total N = 3507 n (%) Healthy controls N = 909
Total n (%)
Children with AOM N = 2598
Total n (%)
p
Demographic characteristics
Sex M 1818 (51.8) 442 (48.6) 1376 (53) 0.02
Mean age ± SD (months) 13.6 ± 5.2 13.1 ± 5.4 13.8 ± 5.1 0.0008
Vaccination with PCV7* 3448 (98.3) 890 (97.9) 2558 (98.5) 0.2
Partial 754 (21.9) 149 (16.7) 605 (23.7)
Complete 2693 (78.1) 741 (83.3) 1952 (76.3)
Type of care <0.0001
Day care centre 1170 (33.4) 138 (15.2) 1032 (39.7)
Childminder 1127 (32.1) 316 (34.8) 811 (31.2)
Home 1209 (34.5) 455 (50.1) 754 (29.1)
Siblings 1906 (54.3) 420 (46.2) 1486 (57.2) <0.0001
Use of Antibiotics 3 months before 1439 (41.0) 195 (21.5) 1244 (47.9) <0.0001
Nasopharyngeal carriage
S. pneumoniae 1780 (50.8) 270 (29.7) 1510 (58.1) <0.0001
Penicillin susceptibility** 0.0001
Susceptible 974 (54.9) 182 (68.2) 792 (52.6)
Intermediate 732 (41.3) 76 (28.5) 656 (43.5)
Resistant 67 (3.8) 9 (3.3) 58 (3.9)
Haemophilus influenzae 1399 (39.9) 130 (14.3) 1269 (48.8) <0.0001
Moraxella catarrhalis 1780 (50.8) 301 (33.1) 1479 (56.9) <0.0001
Staphylococcus aureus 235 (6.7) 99 (10.9) 136 (5.2) <0.0001
Multiple carriage (ie at least two species) 1715 (48.9) 213 (23.4) 1502 (57.8) <0.0001
No bacteria identified 563 (16.1) 376 (41.4) 187 (7.2) <0.0001
* missing data for PCV7 vaccination status: n = 1
**missing data for penicillin susceptibility: n = 7
Figure 1 Serotypes distribution among the pneumococcal carriers according to penicillin resistance.
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Page 3 of 6Table 2 Risk factors for carriage of S. pneumoniae, penicillin non susceptible S. pneumoniae (PNSP), serotype 19A, and
penicillin non susceptible (PNS) serotype 19A
Univariate analysis Multivariate analysis
OR [95% CI] P OR [95% CI] P
Carriage of Sp (n = 1780)
AOM 3.28 2.79;3.86 <0.0001 2.98 2.49;3.56 <0.0001
Day care centre 1.37 1.26;1.48 <0.0001 1.55 1.32;1.82 <0.0001
Siblings 1.58 1.39;1.81 <0.0001 1.63 1.41;1.89 <0.0001
Carriage of M. catarrhalis 1.83 1.60;2.09 <0.0001 1.46 1.27;1.69 <0.0001
Age <12 months 1.02 0.89;1.16 0.78 1.12 0.96;1.30 0.16
Carriage of H. influenzae 1.24 1.08;1.41 0.002 0.81 0.69;0.94 0.006
Recent use of antibiotic 1.07 0.94;1.23 0.31 0.75 0.65;0.87 <0.0001
Carriage of S. aureus 0.50 0.38;0.66 <0.0001 0.62 0.46;0.83 0.001
Partial vaccination 1.28 0.75;2.18 0.37 1.25 0.70;2.20 0.45
Carriage of PNSP (n = 799)
AOM 3.67 2.89;4.66 <0.0001 3.09 2.39;3.98 <0.0001
Day care centre 1.52 1.38;1.68 <0.0001 1.70 1.42;2.03 <0.0001
Siblings 1.06 0.90;1.24 0.5 1.07 0.91;1.27 0.8
Carriage of M. catarrhalis 1.51 1.29;1.77 <0.0001 1.15 0.97;1.37 0.09
Age <12 months 1.06 0.90;1.24 0.5 1.24 1.04;1.49 0.018
Carriage of H. influenzae 1.18 1.00;1.38 0.043 0.82 0.69;0.97 0.002
Recent use of antibiotic 1.63 1.39;1.91 <0.0001 1.24 1.05;1.47 0.011
Carriage of S. aureus 0.72 0.51;1.02 0.062 0.90 0.63;1.29 0.57
Partial vaccination 1.69 0.84;3.40 0.142 1.56 0.76;3.22 0.25
Carriage of serotype 19A (n = 365) in overall population (n = 3507)
AOM 3.89 2.70;5.61 <0.0001 3.26 2.22;4.80 <0.0001
Day care centre 1.63 1.42;1.87 <0.0001 1.85 1.46;2.35 <0.0001
Siblings 0.73 0.58;0.90 0.004 0.74 0.59;0.93 0.009
Carriage of M. catarrhalis 1.50 1.20;1.87 <0.0001 1.10 0.87;1.39 0.40
Age <12 months 1.20 0.97;1.50 0.09 1.48 1.16;1.90 0.002
Carriage of H. influenzae 1.02 0.81;1.27 0.88 0.73 0.57;0.92 0.008
Recent use of antibiotic 1.92 1.55;2.3 <0.0001 1.49 1.19;1.88 0.001
Carriage of S. aureus 0.66 0.39;1.08 0.10 0.80 0.48;1.35 0.41
Partial vaccination 3.81 0.91;15.89 0.066 3.66 0.86;15.49 0.08
Carriage of serotype 19A (n = 365) among Sp carriers (n = 1780)
AOM 2.02 1.38;2.97 0.012 1.67 1.11;2.49 0.012
Day care centre 1.41 1.22;1.63 0.001 1.56 1.21;2.02 0.001
Siblings 0.52 0.41;0.65 <0.0001 0.56 0.44;0.71 <0.0001
Carriage of M. catarrhalis 1.09 0.86;1.37 0.49 0.96 0.75;1.22 0.73
Age <12 months 1.22 0.97;1.53 0.09 1.51 1.16;1.97 0.003
Carriage of H. influenzae 0.89 0.71;1.13 0.34 0.83 0.65;1.07 0.15
Recent use of antibiotic 2.00 1.59;2.53 <0.0001 1.81 1.42;2.30 <0.0001
Carriage of S. aureus 1.02 0.59;1.77 0.93 1.11 0.63;1.96 0.37
Partial vaccination 3.69 0.86;15.85 0.079 3.57 0.81;15.80 0.09
Carriage of PNS serotype 19A (n = 326) among PNSP carriers (n = 799)
AOM 1.89 1.15;3.10 0.012 1.55 0.92;2.61 0.09
Day care centre 1.29 1.09;1.54 0.004 1.39 1.01;1.89 0.04
Siblings 0.52 0.39;0.70 <0.0001 0.57 0.43;0.77 <0.0001
Carriage of M. catarrhalis 1.04 0.78;1.39 0.79 0.96 0.71;1.30 0.77
Age <12 months 1.17 0.88;1.55 0.29 1.29 0.93;1.79 0.13
Carriage of H. influenzae 0.86 0.64;1.14 0.3 0.80 0.59;1.09 0.16
Recent use of antibiotic 1.59 1.20;2.11 0.001 1.46 1.08;1.97 0.013
Carriage of S. aureus 0.79 0.41;1.50 0.46 0.86 0.44;1.68 0.66
Partial vaccination 2.72 0.56;13.16 0.21 2.56 0.51;12.94 0.3
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strains predominated among other serotypes that have
expanded to a lesser extent [19]. Here we investigated
other potential risk factors for 19A carriage.
In our population of children aged from 6 to 24
months with a high rate of PCV7 vaccine coverage, we
confirmed the importance of antibiotic exposure, and
also found a role of DCC attendance and AOM.
Several studies have shown that DCC attendance
increases the risk of pneumococcal carriage [8,20]. How-
ever, this is the first time that DCC attendance has been
specifically linked to increased 19A carriage (OR = 1.85,
95% CI [1.46-;2.35]). The explanation is not only that
DCC attendance increased the overall risk of pneumo-
coccal colonization, and 19A was the most frequently
carried serotype in this population of highly PCV7-vacci-
nated children. In addition, 19A was the most prevalent
serotype in the subpopulation of DCC attendees carrying
pneumococci (OR = 1.56, 95% CI [1.21-;2.02]). The fact
that 19A is frequently resistant to antibiotics and that
DCC attendees have higher antibiotic exposure does not
fully explain our observations. Indeed, 19A carriage was
also the most prevalent serotype among carriers of resis-
tant strains (OR = 1.39, 95% CI [1.01-;1.89]). The propor-
tion of children attending DCC in a given country may
thus influence the observed increase in 19A disease.
Children with AOM were also more likely to carry
serotype 19A. As 19A has already shown to be the most
frequent middle-ear-fluid isolate in PCV7-vaccinated
children, this result might have been expected. However,
our results also support the hypothesis that 19A has
higher AOM disease potential than other non vaccine
serotypes [6].
The main limitation of our study is the homogeneity
of our population (children aged 6 to 24 months, PCV7-
vaccinated, without antibiotics exposure within 7 days
before enrolment, and with no severe underlying health
disorders) making it more difficult to extrapolate our
findings to other populations. Furthermore, our study is
based on nasopharyngeal carriage results and cannot be
directly extrapolated to invasive pneumococcal disease
or middle-ear infections. Future implementation of a
pneumococcal conjugate vaccine that includes a 19A
conjugate may resolve the problems posed by serotype
19A, provided such a vaccine has a significant impact
on 19A carriage. Ongoing surveillance of carriage is
therefore necessary, because the primary pneumococcal
reservoir is the nasopharynx of children. Hence, early
insight into post-vaccine effects can be obtained by
monitoring changes in pediatric carriage.
Conclusion
Our study shows that in a population of children aged
from 6 to 24 months with a high rate of PCV7
vaccination coverage, antibiotic exposure, DCC atten-
dance and AOM are linked to 19A carriage.
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